Mesenchymal stem cell-derived exosomes as new remedy for the treatment of inflammatory eye diseases

Biocell

article

CARL RANDALL HARRELL¹  ANA VOLAREVIC²  DRAGICA PAVLOVIC³  VALENTIN DJONOV⁴  VLADISLAV VOLAREVIC⁴ 

[1]Regenerative Processing Plant

[2]Department of Cognitive Psychology, Faculty of Medical Sciences, University of Kragujevac

[3]Institute of Anatomy, University of Bern

[4]Department of Genetics, Faculty of Medical Sciences, University of Kragujevac

[5]Department of Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac

关键词: Mesenchymal stem cells;    Exosomes;    Inflammation;    Eye;    Therapy;   

DOI  :  10.32604/biocell.2022.020175

学科分类：仪器

来源: Biocell

【 摘 要 】

Detrimental immune response has a crucially important role in the development and progression of inflammatory eye diseases. Inflammatory mediators and proteolytic enzymes released by activated immune cells induce serious injury of corneal epithelial cells and retinal ganglion cell which may result in the vision loss. Mesenchymal stem cells (MSCs) are regulatory cells which produce various immunosuppressive factors that modulate phenotype and function of inflammatory immune cells. However, several safety issues, including undesired differentiation and emboli formation, limit clinical use of MSCs. MSC-derived exosomes (MSC-Exos) are nano-sized extracellular vesicles which contain all MSC-derived immunoregulatory factors. Intraocular administration of MSC-Exos efficiently attenuated eye inflammation and significantly improved visual acuity in experimental animals without causing any severe side effects. As cell-free product, MSC-Exos addressed all safety issues related to the transplantation of MSCs. Therefore, MSC-Exos could be considered as potentially new remedy for the treatment of inflammatory eye diseases which efficacy should be explored in up-coming clinical trials.

【 授权许可】

CC BY